LSD analog shows potential for treating schizophrenia

News
1
6 Likes
2

155544444444444
:flushed_face:

1 Like
3

:face_with_peeking_eye::thinking::saluting_face::face_in_clouds:
Das too scare
15151515

4

Don’t think I’d ever come back if I took this.

1 Like
5
  • JRT and LSD have the exact same molecular weight and overall shape, but distinct pharmacological properties.
  • JRT is very potent and highly selective for binding to serotonin receptors, specifically 5-HT2A receptors, the activation of which are key to promoting cortical neuron growth.
  • JRT promoted neuroplasticity, or growth between cellular connections in the brain, leading to a 46% increase in dendritic spine density and an 18% increase in synapse density in the prefrontal cortex.
  • JRT did not produce hallucinogenic-like behaviors that are typically seen when mice are dosed with LSD.
  • JRT did not promote gene expression associated with schizophrenia. Such gene expression is typically amplified with LSD use.
  • JRT produced robust anti-depressant effects, with it being around 100-fold more potent than ketamine, the state-of-the-art fast-acting anti-depressant.
  • JRT promoted cognitive flexibility, successfully addressing deficits in reversal learning that are associated with schizophrenia.
2 Likes